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Abstract 
Background & Aims: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder causing 
pulmonary and liver disease. The PiZ mutation results in mis-folded alpha-1 antitrypsin 
protein (Z-AAT) leading to hepatocyte accumulation, fibrosis and cirrhosis. RNAi-based 
therapeutics silencing production of hepatic Z-AAT might benefit patients with AATD-
associated liver disease. This study evaluated an RNAi therapeutic to silence production of 
alpha-1 antitrypsin.  
Methods: Part A of this double-blind first-in-human study randomized 54 healthy volunteers 
(HVs) into single dose cohorts (2 placebo: 4 active), receiving escalating doses of the 
investigational agent ARC-AAT from 0.38 to 8.0 mg/kg or placebo. Part B randomized 11 
PiZZ genotype AATD patients who received up to 4.0 mg/kg or placebo. Patients with 
baseline FibroScan® >11 kPa or FEV1  (forced expiratory volume in one second) < 60% were 
excluded. Assessments included safety, pharmacokinetics, and change in serum alpha-1 
antitrypsin (AAT) concentrations.  
Results: 36 healthy volunteers received ARC-AAT and 18 received placebo (Part A). Seven 
PiZZ individuals received ARC-AAT and 4 received placebo (Part B). A dose-response in 
serum AAT reduction was observed at doses ≥ 4 mg/kg with similar relative reductions in 
PiZZ patients and HVs at 4 mg/kg and a maximum reduction of 76.1% (HVs) vs. 78.8% 
(PiZZ) at this dose. Time for serum AAT return to baseline was similar for HV and PiZZ. 
There were no notable differences between HV and PiZZ safety parameters. The study was 
terminated early due to toxicity findings related to the delivery vehicle (ARC-EX1) seen in a 
non-human primate study.  
Conclusion: PiZZ and HV responded similarly to ARC-AAT. Deep and durable knockdown 
of hepatic AAT production based on observed reduction in serum AAT concentrations was 
demonstrated.  
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Lay Summary: Accumulation of abnormal proteins in the livers of patients with alpha-1 
antitrypsin deficiency may lead to decreased liver function and potentially liver failure. 
Therapeutics targeting the production of these abnormal proteins may be used to prevent or 
treat liver disease in patients with alpha-1 antitrypsin deficiency.  
 
List of Abbreviations: AATD, alpha-1 antitrypsin deficiency; Z-AAT, mutant mis-folded 
protein expressed by Z-allele; HVs, healthy volunteer; ARC-AAT, RNA therapeutic targeting 
alpha-1 antitrypsin; FEV1, forced expiratory volume in one second; AAT, alpha-1 
antitrypsin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ARC-EX1, 
excipient used in ARC-AAT to facilitate siRNA delivery; RNAi, ribonucleic acid 
interference; BMI, body mass index; ER, endoplasmic reticulum; KD, knockdown; siRNA, 
short interfering ribonucleic acid; PK, pharmacokinetics; PBO, placebo; DLT, dose limiting 
toxicity; AE, adverse event; ECG, electrocardiogram; VC, vital capacity; DLCO, diffusing 
capacity of the lungs for carbon monoxide; ATS, American Thoracic Society; ERS, European 
Respiratory Society; SAE, serious adverse event; API, active pharmaceutical ingredient; 
LC/MS/MS, liquid chromatography-mass spectrometry; API-AAT, RNA component of 
ARC-AAT; chol-UNA, cholesterol-conjugated unlocked nucleobase analog; mRNA, 
messenger RNA; SOC, system organ class; MLP, mellitin like peptide; Cmax, maximum 
serum concentraction; Tmax, time to reach Cmax; AUC0-24, area under the curve from 0-24 
hours; AUCinf, area under the curve time 0 to infinity; t1/2, half-life; PD, pharmacodynamic; 
ELF, enhanced liver fibrosis panel 
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Introduction 
 
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disease which 
predisposes to early-onset emphysema and liver cirrhosis [1]. Estimates of the number of 
adult AATD patients exhibiting clinically significant liver disease have varied from 10% 
(defined by transaminase abnormalities) [2, 3] to 18% in a U.K. cohort assessed by 
ultrasound (+/- biopsy) [4] to approximately 35% in those with an Ishak fibrosis score  2 
assessed histologically after liver biopsy [5]. A Swedish autopsy series from AATD patients 
with the PiZZ genotype found liver disease to be present in the majority of patients, albeit 
unrecognized in many cases during life [6]. In common with other causes of cirrhosis, many 
factors are thought to affect clinical presentation, including alcohol use [7], BMI [8], gender 
[9] and genetic modifiers. Liver disease shows a bimodal clinical presentation. Prolonged 
neonatal jaundice is common in newborns with the PiZZ genotype, with most recovering but 
others progressing to cirrhotic disease that requires transplantation at a young age [10, 11]. A 
second peak occurs in adults who can present with clinical liver disease that can also progress 
to cirrhosis and transplant, even in the absence of a childhood history of liver disease [3]. No 
definitive methods to predict progression to cirrhosis exist at present in either the pediatric or 
adult populations. Current management of liver disease in AATD is largely supportive, with 
transplantation the only definitive treatment. In the U.S., AATD accounts for approximately 
1.5% of liver transplants with ~76 transplants performed annually [12] with outcomes similar 
to other common indications for transplant [13].  
The most common genetic variant of alpha-1 antitrypsin (AAT) associated with liver 
disease is the PiZ allele whose protein product misfolds and forms polymers that are retained 
within the endoplasmic reticulum (ER) of hepatocytes and can be seen as periodic acid-
Schiff-positive inclusions in biopsies of AATD livers [14]. Drugs targeting polymerization, 
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as well as those that influence cellular homeostasis mechanisms which target disposal of the 
mutant protein aggregates (such as autophagy) represent potential novel therapeutic routes 
[14]. Another route to reduce AAT polymers would be to limit production of alpha-1 
antitrypsin  protein by interfering with its mRNA using antisense or RNA interference target 
knockdown (KD) approaches. This KD method has demonstrated reduced accumulation of 
mutant protein globules and inhibited expression of fibrosis-associated genes in the PiZZ 
transgenic mouse [15]. We report here results of a randomized, placebo-controlled phase 1 
study in healthy volunteers (HVs) and PiZZ AATD individuals administered ARC-AAT, a 
short interfering RNA (siRNA) therapeutic targeting liver production of AAT. Preclinical 
animal studies with ARC-AAT will be reported elsewhere. 
 
Materials and Methods 
 
This was a multi-center, randomized, placebo-controlled, double-blind, single dose-
escalation, first-in-human, Phase 1 study (NCT02363946) conducted to evaluate the safety, 
tolerability, pharmacokinetics (PK) and effect on circulating AAT levels of the 
investigational product, ARC-AAT, administered intravenously to healthy volunteers (Part 
A) and to PiZZ patients with AATD (Part B). Part A was initiated in HVs and Part B in 
individuals with AATD. With the intention of not enrolling rare disease patients at doses 
unlikely to have activity, Part B proceeded once target serum AAT KD of at least 30% in 
three of six HVs in a Part A cohort was seen, together with satisfactory safety data. The 
design is summarized in Fig. S1, S2. The study was approved by the appropriate institutional 
review committee at each site prior to commencement. Written informed consent was 
obtained from each subject included in the study and the study protocol conforms to the 
ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by 
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each institution’s human research committee. Participants who met all eligibility criteria (see 
Supplementary methods) were randomized using block randomization at a ratio of 2:1 
(active:placebo) to receive a single intravenous injection of either placebo (PBO) or ARC-
AAT in double-blind fashion. The study allocation sequence was generated and patients were 
assigned to study groups by an un-blinded statistician at the contract research organization 
(CPR Pharma, Adelaide, Australia). The study investigator at each site enrolled all study 
participants. Once screened, eligible participants were allocated to a sequentially numbered 
treatment and assigned a unique randomization number in accordance with the randomization 
schedule. The study protocol specified that all study participants and investigators remained 
blinded to treatment group throughout the study. The sponsor was permitted to unblind on a 
cohort by cohort basis after all subjects in a cohort completed their final study visit. The first 
study participant was enrolled December 5
th
, 2014 and the last participant follow up visit was 
November 18
th
, 2016.  
Up to thirteen cohorts (6 participants per cohort) were planned, including 9 HV 
cohorts, with dosing starting at 0.38 mg/kg and escalating through doses of 1.0, 2.0, 3.0, 4.0, 
5.0, 6.0, 7.0 and 8.0 mg/kg. For each participant (both Part A and Part B), clinical facility 
confinement was approximately 2 days, starting on Day 1 with dosing on Day 1 and 
discharge on Day 2. Two sentinel HV participants were dosed at 0.38 mg/kg (one ARC-AAT, 
one PBO) in part A; when no significant safety concerns were raised following Day 3 
evaluation in these participants, the remaining four participants in Cohort 1 were treated. Part 
A participant data were collected at a single Phase 1 facility (Nucleus Networks, Melbourne 
Australia).  
Part B of the study was initiated at the 2 mg/kg dose level with planned PiZZ patient 
cohorts at 2.0, 4.0, 6.0 and 8.0 mg/kg. Escalation to the next dose level proceeded based on 
all available safety data through Day 8 of the current cohort. Provision was made to halt dose 
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escalation if a dose-limiting toxicity (DLT) occurred,  defined as a treatment-related adverse 
event (AE; rated as possibly or probably related) that may have posed an unacceptable risk to 
other participants or if target KD parameters were achieved. Part B participant data were 
collected during patient visits to participating clinical trial sites. Dose escalation through all 
HV cohorts was completed. In PiZZ individuals, the 2.0 mg/kg cohort was completed and 5 
of 6 PiZZ individuals were enrolled into the 4 mg/kg cohort prior to termination of the study.  
 
Study assessments 
 
The safety analysis included all patients who received ARC-AAT or placebo.  Safety 
measures included: (1) AEs; (2) physical examination; (3) vital signs; (4) 12-lead ECG 
measurement; (5) ECG telemetry (8 hours pre-dose to 24 hours post-dose); (6) pulmonary 
function testing (spirometry to include VC, FEV1, FEV1/VC) and DLCO, both conducted in 
accordance with ATS-ERS guidelines; (7) clinical laboratory tests (hematology, 
biochemistry, coagulation, urinalysis); (8) use of concomitant medications, and (9) recording 
reasons for treatment discontinuation. Scheduled evalutaions were performed by a blinded 
member of the site staff. Abnormalities in laboratory findings or other assessments that were 
deemed clinically significant by the study investigator and were initially detected during the 
study or were present at baseline and significantly worsened during the study were reported 
as AEs, whether or not they were considered drug-related by the study investigator. All AEs 
and SAEs were followed until resolution, until the condition stabilized, until the event was 
otherwise explained, or until the subject was lost to follow-up. Quantitative serum AAT was 
assessed by turbidometric and/or nephelometric methods (Roche Cobas

 c501, 
ARCHITECT ci16200™, BN II System). Serum AAT reduction is based on each 
individual’s change from their baseline value with baseline calculated as the geometric mean 
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of three serum AAT measurements prior to receiving test article. Further details on when 
each assay was used and a comparison between platforms can be found in Figs. S3-S5. PK 
samples were analyzed using a validated hybridization-ligation method for the API and a 
validated LC/MS/MS method for the delivery excipient. 
 
Investigational medicinal product 
 
ARC-AAT Injection comprised API-AAT, the Active Pharmaceutical Ingredient consisting 
of a single cholesterol-conjugated unlocked nucleobase analog (chol-UNA) RNAi trigger 
targeting AAT mRNA supplied in a liquid solution, plus the delivery excipient ARC-EX1 
containing hepatocyte-targeted N-acetylgalactosamine-conjugated melittin-like peptide 
supplied as a powder. The vials were prepared by an un-blinded pharmacist in the pharmacy 
under sterile conditions to yield a 2:1 ratio by weight (API-AAT:ARC-EX1) and then 
administered by a blinded site staff member as a single intravenous infusion at a rate of 20 
mg/min. All subjects were treated with an oral antihistamine approximately 2 hours prior to 
infusion.  
 
Objectives 
 
Primary objectives were to determine the safety and tolerability of escalating doses of ARC-
AAT, to evaluate PK of ARC-AAT components at different doses, and to determine the 
effect of ARC-AAT on circulating levels of AAT. Key secondary objectives included 
determining the dose levels achieving >30% KD and ≥ 90% KD of AAT on or before Day 22 
(± 1 day) when compared to the pre-dose geometric mean baseline AAT level in HVs, 
determining the dose level achieving > 90% KD at Day 29 (± 1 day) in 50% of PiZZ 
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individuals and the time for serum AAT levels to return to baseline (± 15% from geometric 
mean baseline or > 90 mg/dL for HV).  
 
Data handling and statistical analysis 
 
No statistical methods were used to determine cohort sizes or total subjects planned for 
enrollment. Safety results were summarized by cohort and treatment group. The frequency of 
treatment-emergent AEs, SAEs, related AEs, related SAEs, and AEs leading to withdrawal, 
dose modification, or treatment discontinuation were summarized by dose and treatment 
group according to the latest version of MedDRA by System Organ Class (SOC) and 
Preferred Term. Plasma concentrations of ARC-AAT Injection constituents (MLP, chol-
UNA) following a single dose of ARC-AAT injection at different dose levels were used to 
calculate the following ARC-AAT PK parameters: Cmax, tmax, AUC0-24, AUCinf, and t1/2. 
Pharmacokinetic parameters were determined using non-compartmental method(s) with 
Phoenix™ WinNonlin® Version 6.3 software (Copyright ©1998-2012, Certara L.P., 
distributed by Pharsight Corporation). Descriptive statistics of PK parameters included mean, 
standard deviation, and coefficient of variation. Pharmacodynamic (PD) analyses were 
performed using Microsoft Excel 2013 and GraphPad Prism software version 6.0. Descriptive 
statistics included geometric mean, mean, standard error of mean, and percent AAT serum 
concentration change from baseline.  
 
Results 
 
Healthy volunteer and PiZZ individual characteristics 
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Fifty-four HVs were enrolled with 36 receiving ARC-AAT and 18 receiving placebo. All 
HVs resided in Australia; characteristics are shown in Table 1. Eleven PiZZ AATD 
individuals were enrolled from patients screened in the United Kingdom, Australia, the 
Netherlands and Germany; their characteristics are shown in Table 1. PiZZ patients included 
in the study had minimal or no liver or lung disease. Baseline FEV1 and FibroScan® 
parameters for individual PiZZ patients are presented in Table 2. The mean PiZZ patient 
FEV1 at baseline was 85% (Range 72-93%). The mean baseline FibroScan® was 5.58 kPa 
(Range 4.0-6.6) which is consistent with very minimal or no liver fibrosis. Seven PiZZ 
individuals received ARC-AAT and 4 received placebo. Fig. S2 presents the Consort diagram 
for the study. 
 
Safety, pharmacokinetics and pharmacodynamics 
 
In both Part A (HV) and Part B (PiZZ), there were no deaths and no serious adverse events 
(SAEs) in subjects receiving ARC-AAT. There was one SAE of rhabdomyolysis in a subject 
receiving placebo. There were no AEs rated as severe in intensity in subjects receiving ARC-
AAT or AEs leading to premature study discontinuation. The only AE showing a pattern 
indicating possible dose relatedness was chills, reported in 3 of 4 HVs at the 8 mg/kg dose 
and likely related to the infusion of ARC-AAT (Tables S1A, B). Headaches, muscle spasms, 
upper respiratory tract infection, nausea and dysmenorrhea were seen more frequently in 
healthy volunteer subjects receiving ARC-AAT. However, there is no clear mechanistic 
association between ARC-AAT and these symptoms. In the AATD patients, no AE occurred 
more than once in the seven subjects receiving ARC-AAT. A single AE with the preferred 
term of “asthma” was reported in an AATD patient receiving 2 mg/kg of ARC-AAT. This 
AE was reported as mild and in a patient with a previous history of asthma treated with 
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inhaled steroids and inhaled β2-receptor agonists. Symptoms began on Day 7 and were 
reported to last approximately 5 minutes, then resolving with use of inhaled beta-agonists. 
The study investigator reported this AE as not related to ARC-AAT but rather related to cold 
air exposure. This patient did not experience any meaningful adverse changes in FEV1 during 
the study. There were no clinically significant adverse changes in ECG, DLCO, or FEV1 and 
no increased rate of pulmonary AEs in subjects receiving ARC-AAT. Baseline and post-dose 
values for FEV1 and select clinical laboratory assessments in HV subjects and PiZZ patients 
are presented in Table S2A, B.  The study was terminated early due to toxicity findings 
related to the delivery vehicle (ARC-EX1) seen in a non-human primate study.  
All subjects randomized to ARC-AAT in Part A had PK concentrations reported for 
all samples collected. One HV dosed at 8.0 mg/kg did not receive a full dose (<50%) and thus 
was excluded from the PK summary. The PK parameters in HVs and patients are shown in 
the Table S3; overall results indicated that the API circulates with a short half-life of 
approximately 4 hours. The delivery excipient, ARC-EX1, demonstrated a half-life of 8-10 
hours. Exposure increased linearly with dose.  
There was a clear PD dose response to ARC-AAT when considering serum AAT 
levels, with prominent (>30%) reductions seen at all doses ≥ 2mg/kg (Fig. 1; Fig. S6). The 
greatest reductions were seen at approximately four weeks post-dose. The time to reach 
maximum serum AAT reduction may be in part due to the 5-7 day half-life of serum AAT. 
Reductions in serum AAT levels achieved in Cohort 3 (2.0 mg/kg) were sufficient to 
transition to Part B of the study based on the criteria pre-defined in the protocol. Continuing 
dose escalation in HVs showed a dose-related response for reduction in serum AAT levels, 
with mean relative maximum reductions of 88.3% seen at the 8.0 mg/kg dose level (Fig. 1; 
Table 3; Fig S6). The relative percentage reduction in AAT for PiZZ patients receiving 2.0 
mg/kg and 4.0 mg/kg ARC-AAT was similar to that in the healthy subjects at the same dose 
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level (Fig. 1). The maximum reduction in a single PiZZ patient was 78.8% at 4.0 mg/kg 
ARC-AAT, compared with 76.1% in HVs at this dose. Although the percentage change in 
serum AAT changes were similar in HV and PiZZ subjects, the baseline and maximum post-
dose reduction absolute values were different. The average baseline serum AAT 
concentration for HV was 144.3 mg/dL (range: 101-216) and for PiZZ was 25.3 mg/dL 
(range: 20.3-35.0) (Fig. S7). The lowest serum AAT concentration reached was 13.2 and 5.9 
mg/dL in HV and PiZZ subjects, respectively.  
 
Dose range to achieve target knockdown  and duration of knockdown  
 
Greater than 30% KD was achieved in HVs at doses of 3.0 mg/kg and above, while 89.8% 
was the maximum KD achieved at 8.0 mg/kg in any subject, with a clear dose response and 
plateau effect at doses ≥6.0 mg/kg (Fig. 1; Table 3). Similar effects in PiZZ patients were 
observed (Fig. 1), although the 90% KD target was not achieved, presumably due to early 
termination of dose escalation. The duration of ≥ 30% KD was around 8 weeks in HVs at 
optimal (≥6 mg/kg) doses, and KD durations were similar in PiZZ and HVs at equivalent 
doses (Fig. 1). 
 
Discussion 
 
The main finding from this randomized, controlled phase 1 study of a hepatocyte-targeted 
RNAi therapeutic was a clear dose response in serum AAT knockdown, with a mean 
maximum knockdown of 88.3% observed at the highest (8 mg/kg) dose level in healthy 
volunteers. A dose response was also seen in PiZZ individuals with maximum serum AAT 
knockdown of 78.8% at the 4 mg/kg dose level. The level of knockdown seen in healthy 
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volunteers and in PiZZ individuals was similar at equivalent doses. In this study, ARC-AAT 
was safe, with no SAEs observed in actively treated subjects while other AEs observed were 
relatively unremarkable (Tables S1A, B). 
Circulating serum AAT levels in healthy adults will generally exceed 90 mg/dL and 
represent a combination of AAT secreted from the liver and extrahepatic sources [16]. Based 
on the plateau in maximum AAT reduction (Fig. 1), it appears that approximately 90% of 
circulating AAT is produced in the liver in phenotypically normal adults. This reduction is 
similar to that observed in transgenic mice transfected with the human PiZ AAT gene when 
they are treated with maximal doses of a hepatic-directed siRNA [17]. Due to the premature 
discontinuation of this clinical trial because of an unexpected animal toxicity seen with a 
different compound sharing the same ARC-EX1 delivery excipient, we were unable to 
evaluate the full dose range in PiZZ AATD patients as planned. As expected from the 
experience in PiZ transgenic mice and HVs, ARC-AAT reduced circulating AAT serum 
concentrations in AATD patients. Comparing percentage reductions for AATD individuals 
and HVs (Fig. 1; Table 3), PiZZ individuals responded at least as well to ARC-AAT with 
respect to both depth and duration of AAT knockdown. Similar results have been reported by 
other groups developing siRNA therapeutics targeting hepatic alpha-1 antitrypsin production 
[18].  
The method used for AAT knockdown involved the active agent (API) and a delivery 
excipient (ARC-EX1). The API consisted of a single cholesterol-conjugated unlocked 
nucleobase analog (chol-UNA) targeting AAT mRNA. The RNAi trigger was conjugated to 
cholesterol to increase the uptake of API in the liver by endocytosis while the delivery 
excipient, also targeted to the liver by conjugation to N-acetylgalactosamine, enabled 
endosomal escape of the siRNA into the cytoplasm where RNAi occurs [19]. This approach 
was effective in that it resulted in significant knockdown of AAT in both HVs and PiZZ 
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patients. This indicates that RNAi is a viable strategy for further development for the 
reduction of AAT hepatic synthesis.   
AATD predisposes to emphysema because of an inadequate protease screen in the 
lung, leaving neutrophil elastase unchecked and resulting in loss of alveolar walls. In contrast 
to the toxic loss of function that defines the emphysema risk in AATD, the pathogenesis of 
liver disease relates to a toxic gain of function related to the inability to secrete polymerized 
AAT that accumulates in the hepatocyte with specific alpha-1 antitrypsin variants, leading to 
endoplasmic reticulum stress, fibrosis, and ultimately cirrhosis. A recent cross-sectional study 
of adult AATD patients demonstrated that advanced fibrosis can be present without clinical 
manifestations of disease [5]. However, liver fibrosis and even cirrhosis may regress with 
removal of the hepatic insult which supports silencing hepatic alpha-1 antitrypsin production 
in patients with liver disease [20]. Survival in AATD patients is increasing, likely due to less 
smoking, reduced exposure to inhaled environmental toxins and better pulmonary care [21].  
With improvement in lung disease-related mortality, it seems likely that liver disease will be 
increasingly recognized in PiZZ adults in the future. The only options currently available for 
patients with AATD-associated liver disease include standard supportive care (e.g. avoidance 
of hepatic toxins and vaccination) and liver transplant. The development of RNAi 
therapeutics targeting the hepatic production of Z-AAT protein would represent a novel 
approach to preventing and potentially reversing AATD-associated liver disease. The results 
from this first-in-human study are encouraging in that they demonstrate potent and prolonged 
reduction of hepatic AAT synthesis as measured by serum AAT levels. This first-in-human 
study of an RNAi therapeutic may represent a first step in the development of a new class of 
hepatocyte-targeted therapeutics for the treatment of AATD-associated liver disease. 
Detecting AATD liver disease is generally based on clinical suspicion. Optimal 
strategies to image the liver for early detection of fibrosis in AATD, as are recognized in 
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many other fibrotic liver conditions [22], are not yet established [23]. Subjects included in 
our study did not have clinically significant liver disease, based on either clinical evaluation 
or on transient elastography (FibroScan®) at screening. This and the phase 1 single escalating 
dose design precludes any conclusions being drawn about the efficacy of ARC-AAT in 
reducing liver pathology. Future multi-dose studies of siRNA drug candidates for AATD 
liver disease will likely need to demonstrate a histologic benefit based on liver biopsy, a 
reduction in the rates of liver-related events (e.g. variceal bleed or transplant) or a major 
effect on surrogate outcomes such as elastography or other biomarkers. A small study of the 
enhanced liver fibrosis panel (ELF) as a biomarker in AATD patients has been published 
[24], but further work is needed to understand if this would be a viable, less invasive 
alternative to biopsy.  
With termination of all ARC-EX1 containing programs by the study sponsor due to 
ARC-EX1 delivery excipient-related toxicity findings in a non-clinical study, further 
development of RNAi mediated knockdown of AAT is ongoing utilizing strategies which do 
not require a delivery excipient. In addition to an expected reduction in toxicity, this newer 
method in pre-clinical development can potentially use subcutaneous rather than intravenous 
administration.  
One concern facing this strategy is the potential that knockdown of AAT may 
increase the risk of lung disease in AATD patients if used chronically, since participants with 
null genotypes who produce no AAT in any tissue exhibit more severe emphysema [25]. In 
this study, no significant adverse changes in lung function were seen, although we recognize 
that the short duration of treatment was insufficient to fully examine for changes in lung 
function. To mitigate concerns of RNAi-induced reductions in serum AAT in AATD 
participants with pre-existing emphysema, AAT augmentation therapy could be used 
concomitantly with liver-targeted siRNA therapeutics intended to treat liver disease [26]. It 
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should also be emphasized that the AATD patients treated in this study by design were 
relatively healthy with minimal lung or liver disease based on standard non-invasive 
measures. The safety and pharmacodynamic response of this approach will need to be 
evaluated in patients with more advanced lung and liver disease.   
Strengths of our study include the large number of HVs tested, the wide range of 
doses studied and the inclusion of PiZZ subjects in the age group where such a product would 
likely be used. Limitations include the early study termination, short duration of treatment 
and the lack of liver biopsy outcomes in participants. However, we believe that liver biopsy 
would not have been appropriate prior to phase 2 work due to its invasive nature, its 
corresponding procedural risk, and uncertain therapeutic benefit in this single dose phase 1 
study that enrolled relatively healthy PiZZ subjects.  
In conclusion, RNAi can be used to reduce hepatic production of AAT based on dose 
responsive reductions in serum AAT levels seen after administration of single doses of ARC-
AAT, and siRNA shows promise for treatment of AATD-associated liver disease. 
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Figure Legends 
 
Title:  
Fig. 1: Serum AAT dose response to ARC-AAT in healthy volunteers and PiZZ 
subjects.  
Legend: 
A single intravenous dose of (A) 0.38 to 8.0 mg/kg ARC-AAT (Cohorts 1-3g) was given to 
healthy volunteers, and (B) 2 and 4 mg/kg ARC-AAT (cohorts 4 and 5) given to PiZZ 
subjects. Serum AAT was measured weekly for the first four-weeks and then bi-weekly until 
serum concentrations returned to baseline. (C) Duration of knockdown in healthy volunteers 
and PiZZ subjects was similar.  Mean line plotted when n>1 at time point. Subjects receiving 
ARC-AAT per dose level, n=3-4 (healthy volunteers), n=3 (PiZZ), receiving placebo, n=18 
(healthy volunteers), n=4 (PiZZ). Legend doses are in mg/kg. Data represents the mean ± 
SEM. Abbreviations: PBO, Placebo; HV, healthy volunteers; ZZ, PiZZ subjects. 
  
  
22 
 
Table 1: Characteristics of the participants 
Legend: Numerical values are shown as mean (SD) and frequency variables as n (%) 
Dose (mg/kg) 
N = HV, PiZZ 
0.38 
n=4 
1.0 
n=4 
2.0 
n=4, 4 
3.0 
n=4 
4.0 
n=4, 3 
5.0 
n=4 
6.0 
n=4 
7.0 
n=4 
8.0 
n=4 
Total 
n=36, 
7 
Placebo 
n=18, 4 
All 
n=54, 11 
HVs Mean age 
in years 
(SD) 
39.0 
(9.8) 
25.0 
(4.5) 
30.0 
(7.8) 
29.5 
(10.7) 
32.3 
(5.6) 
23.8 
(4.1) 
32.5 
(15.3) 
26.0 
(5.0) 
25.0 
(1.8) 
29.2 
(8.6) 
25.4 
(4.8) 
28.0 
 (7.7) 
Mean BMI 
(SD) 
25.28 
(2.92) 
21.48 
(1.36) 
23.10 
(3.38) 
23.75 
(2.70) 
23.45 
(2.01) 
21.75 
(2.08) 
23.85 
(1.61) 
22.53 
(2.03) 
23.65 
(3.47) 
23.20 
(2.46) 
23.38  
(2.37) 
23.26 
(2.41) 
Male  3 
(75%) 
0 2 
(50%) 
3 
(75%) 
3 
(75%) 
0 1 
(25%) 
1 
(25%) 
2 
(50%) 
15 
(42%) 
6 
(33%) 
21 
(39%) 
Mean 
baseline 
serum 
AAT, 
mg/dL (SD) 
119 
(12.2) 
154 
(29.1) 
119 
(15.6) 
137 
(12.1) 
140 
(20.5) 
183 
(36.4) 
151 
(27.1) 
164 
(22.0) 
141 
(17.3) 
145 
(29.3) 
143 
(23.0) 
145 
(27.3) 
PiZZ 
patients 
Mean age 
in years 
(SD) 
 
 
59.0 
(1.8) 
 64.3 
(3.8) 
 61.3 
(3.8) 
58.8 (9.0) 60.4 
(5.9) 
Mean BMI 
(SD) 
 27.50 
(3.56) 
 24.10 
(2.63) 
 26.04 
(3.46) 
26.43 
(2.73) 
26.18 
(3.07) 
Male   1(25%)  2 (67%)   1 (25%) 4 (36%) 
Mean 
Baseline 
FEV1%*  
(Range) 
 85 (72-
93) 
 91 (78-
104) 
 87.57 
(72-
104) 
93.25 (80-
104) 
89.64 
(72-104) 
Mean 
baseline 
DLCO%** 
(Range) 
 65.75 
(57-73) 
 63.33 
(51-73) 
 64.71 
(51-
73) 
68.5 (43-
105) 
66.09 
(43-105) 
Mean 
baseline 
serum 
AAT, 
mg/dL (SD) 
 25.2 
(6.1) 
 27.4 
(2.9) 
 26.2 
(5.0) 
24.3 
(4.4) 
25.5 
(4.8) 
Mean 
baseline 
FibroScan® 
kPa 
(Range) 
 5.58 
(4.0-6.6) 
 5.57 
(5.0-
6.1) 
 5.57 
(4.0-
6.6) 
5.58 (4.1-
7.5) 
5.57 
(4.0-7.5) 
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Table 2: Individual PiZZ patients baseline measures of lung and liver disease severity. 
Legend: FEV1% = forced expiratory volume in one second as a % of predicted 
PiZZ 
Patient 
Gender Age Baseline FEV1% Baseline FibroScan® (kPa) ALT (U/L) Day 1 pre-dose 
Patient 1 Female 58 93 5.5 19 
Patient 2 Female 64 80 5.5 17 
Patient 3 Female 57 72 6.6 17 
Patient 4 Male 61 84 6.2 19 
Patient 5 Female 60 91 4.0 27 
Patient 6 Female 59 97 5.2 23 
Patient 7 Male 66 78 5.6 17 
Patient 8 Female 66 92 4.1 12 
Patient 9 Male 60 104 5.0 38 
Patient 10 Female 67 91 6.1 17 
Patient 11 Male 46 104 7.5 24 
 
  
  
24 
 
Table 3: Maximum serum AAT KD across dose levels in healthy volunteers and PiZZ 
individuals 
Legend: Abbreviations: KD, knockdown; HV, healthy volunteers; ZZ, PiZZ patients 
Dose Level 
(mg/kg) 
PBO 0.38 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 
HV (n) 18 4 4 4 4 4 4 4 3 3 
Max KD 
(%) 
24.8 9.30 31.9 36.3 61.0 76.1 86.7 87.1 85.1 89.8 
Mean Max 
KD (%) 
(SEM) 
8.44 
(1.80) 
6.55 
(1.49) 
25.9 
(3.29) 
26.7 
(7.14) 
45.3 
(6.80) 
64.8 
(6.07) 
78.1 
(4.38) 
83.3 
(1.93) 
82.6 
(1.31) 
88.3 
(0.769) 
P value N/A 0.6363 0.0004 0.0014 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
ZZ 4 - - 3 - 3 - - - - 
Max KD 
(%) 
46.6 - - 73.7 - 78.8 - - - - 
Mean Max 
KD (%) 
(SEM) 
21.9 
(9.81) 
- - 
44.1 
(15.1) 
- 
78.1 
(0.481) 
- - - - 
P value N/A - - 0.2524 - 0.0047 - - - - 
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Article Highlights: 
 Alpha-1 antitrypsin deficiency is associated with liver fibrosis and cirrhosis 
 RNAi drugs might benefit patients with alpha-1 antitrypsin deficiency  
 ARC-AAT reduced alpha-1 antitrypsin protein in study participants  
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